AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Individualised Blood Pressure Targets Versus Standard Care Among Critically Ill Patients With Shock

RecruitingNAAges 40 Years - anyAllRakshit Panwar
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Aim The aim of the proposed RCT is to determine effectiveness of a strategy, where MAP (mean arterial blood pressure) targets during vasopressor therapy for shock in ICU are individualized based on patients' own pre-illness MAP that would be derived as an average of up to five most recent pre-illness blood pressure readings. Hypothesis We hypothesize that targeting a patient's pre-illness MAP during management of shock can minimize the degree of MAP-deficit (a measure of relative hypotension), which may help reduce the risk of 14-day mortality and major adverse kidney events by day 14 in ICU. Endpoints The primary endpoint will be the all-cause mortality rate at day 14. Secondary endpoints will be the time to death through day 14 and day 90, major adverse kidney events (MAKE-14), renal replacement therapy (RRT) free days until day 28, and 90-day all-cause mortality. Significance To da

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * ICU patients aged greater than or equal to 40 years * The patient is deemed to be in shock, defined as clinician-initiated vasopressor/inotropic therapy AND supported by any of the following within the last 24 hours: * Lactate level greater than or equal to 2 mmol/l or base deficit greater than or equal to 3 mmol/l, * Urine output less than or equal to 0.5 ml/kg/h or \<40 ml/h for 2 or more consecutive hours * Respiratory rate \>22 per minute * Altered mentation (Glasgow Coma Score \<14) Exclusion Criteria: * Patients who are moribund, or have documented not-for-resuscitation orders * At least 24 hours have lapsed from the time of initiation of vasopressor or inotropic support * Patients who are either receiving or are deemed to imminently need renal replacement therapy. * Patients who already have an increase in serum creatinine of \>350 ยตmol/l from baseline. * End stage renal disease * Patients where trauma is the main reason for the current ICU admission. * Previously enrolled in the REACT Shock RCT * Pregnancy, if known * Active bleeding (clinical suspicion or \>2 packed red blood cells within last 24 hours) * Insufficient (less than two) pre-illness BP readings are available. * Patients on extracorporeal support (such as extracorporeal membrane oxygenation, intra-aortic balloon pump, or ventricular assist device). * Potential contraindications to either higher or lower BP targets (including but not limited to) * Cerebral perfusion pressure guided therapy e.g. intracranial hemorrhage or subarachnoid hemorrhage or traumatic brain injury * Abdominal perfusion pressure guided therapy * Aortic injury (e.g. dissection or post-operative) * Post cardiac surgery * Any other condition requiring higher or lower BP target specifically
๐Ÿ’Š

What it tests

  • Individualised MAP target
๐Ÿ“

Where

1 site
Hunter Medical Research Institute
Newcastle, Australia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy